Drug intelligence / Profile preview

Venezuelan equine encephalitis virus DNA vaccine

Development stage: Phase 1
Lead developer: U.S. Army Medical Research Institute of Infectious Diseases
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The Venezuelan equine encephalitis virus (VEEV) DNA vaccine is a prophylactic genetic immunization designed to protect against infection by the mosquito-borne alphavirus VEEV. The most studied constructs encode the codon-optimized envelope glycoprotein genes or the full 26S structural gene region (C-E3-E2-6K-E1) of the IAB strain Trinidad donkey of VEEV. Delivered via intramuscular electroporation or jet injection, this DNA vaccine induces robust humoral and cellular immune responses in animal models and has advanced to Phase 1 human clinical trials. It elicits strong neutralizing antibody titers and Th1-type cellular immunity, providing complete protection from lethal aerosol challenge in mice and significant protection in non-human primates. The mechanism of action is based on expression of viral antigens from transfected host cells leading to an adaptive immune response targeting VEEV[1][3][4][5][6].

Other names: Venezuelan Equine Encephalitis DNA VaccineVEE virus DNA vaccine encoding 26S

Targets

VEEV E1 (Venezuelan equine encephalitis virus E1 glycoprotein)Venezuelan equine encephalitis virus E2 envelope glycoprotein

Beyond the preview

Go deeper on Venezuelan equine encephalitis virus DNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Venezuelan equine encephalitis virus DNA vaccine.

Explore the full profile